Want to see TSE:VXL full AI Analyst Report?
Top Page
Vaxil Bio
(VXL)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.15
▼(-6.88% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance—no revenue, persistent operating losses, and ongoing cash burn—despite a debt-free balance sheet. Technicals are broadly neutral with no strong trend, and valuation appears optically cheap on P/E but is less compelling given earnings-quality and pre-commercialization risk.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces solvency risk and eliminates interest expense, preserving financial flexibility while the company funds clinical development. Positive equity provides a capital base, although fluctuations mean this strength should be monitored as research spending continues.
Negative Factors
No reported revenue
The absence of reported revenue indicates that Vaxil Bio has not yet demonstrated commercial operating traction. Without product sales or recurring revenue, financial progress depends on advancing candidates toward commercialization or securing external funding and partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces solvency risk and eliminates interest expense, preserving financial flexibility while the company funds clinical development. Positive equity provides a capital base, although fluctuations mean this strength should be monitored as research spending continues.
Read all positive factors
Vaxil Bio (VXL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$597.60K
Dividend YieldN/A
Average Volume (3M)1.50K
Price to Earnings (P/E)1.5
Beta (1Y)-0.95
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees3
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.10
Shares Outstanding3,984,020
10 Day Avg. Volume3,872
30 Day Avg. Volume1,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaxil Bio Business Overview & Revenue Model
Company Description
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically inf...
How the Company Makes Money
Publicly available information sufficient to describe Vaxil Bio’s recurring, product-based revenue streams is null. As a clinical-stage/early-stage biotechnology company, its potential (and typical) monetization pathways would generally include (i...
Vaxil Bio Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -2.00K | -25.00K |
| EBITDA | -255.00K | -179.00K | -178.00K | -252.00K | -582.00K | -961.00K |
| Net Income | 387.00K | 522.00K | -178.00K | -254.00 | -584.00K | -986.00K |
Balance Sheet | ||||||
| Total Assets | 1.22M | 1.37M | 733.00K | 976.00K | 1.54M | 2.29M |
| Cash, Cash Equivalents and Short-Term Investments | 464.00K | 671.00K | 714.00K | 938.00K | 1.51M | 2.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 30.00K | 5.00K | 17.00K | 85.00K | 405.00K | 585.00K |
| Stockholders Equity | 1.19M | 1.36M | 716.00K | 891.00K | 1.14M | 1.70M |
Cash Flow | ||||||
| Free Cash Flow | -276.00K | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Operating Cash Flow | -276.00K | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Investing Cash Flow | 266.00K | 266.00K | -250.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 127.00K | 127.00K | 0.00 | 0.00 | 0.00 | 1.81M |
Vaxil Bio Technical Analysis
Negative
0.16
Price Trends
0.17
Negative
0.20
Negative
0.17
Negative
Market Momentum
>-0.01
Positive
33.36
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VXL, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.17, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.36 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VXL.
Vaxil Bio Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | C$43.85M | -0.30 | -147.92% | ― | ― | 85.31% | |
48 Neutral | C$597.60K | 1.50 | 34.52% | ― | ― | ― | |
46 Neutral | C$32.21M | -1.88 | -360.29% | ― | ― | -33.27% | |
42 Neutral | C$36.38M | -4.30 | -1661.38% | ― | ― | -40.15% | |
29 Underperform | C$2.04M | -0.91 | 69.89% | ― | ― | ― |
* General Sector Average
TSE:VXL
Vaxil Bio
0.15
-0.05
-25.00%
TSE:MDNA
Medicenna Therapeutics Corp
0.42
-0.64
-60.48%
TSE:BCT
BriaCell Therapeutics
5.04
-5.99
-54.31%
TSE:BIOV
BioVaxys Technology
0.07
-0.16
-68.89%
TSE:DTC
Defence Therapeutics
0.48
-0.25
-34.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.